{"formatVersion":"1.1","id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents","path":"/library/antiparkinson-agents","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents","title":"Antiparkinson Agents","family":"Library detail","description":"Explore medication options for Parkinson's disease, including levodopa and supportive therapies to manage symptoms.","language":"en-US","access":{"audience":"custom-shared-preview","indexable":true},"provenance":{"sourceUrl":"https://www.mentalhealth.com/library/antiparkinson-agents","wordpressId":"9036","contentCompleteness":"complete","dateScope":"original-source"},"authors":[{"@type":"Person","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong#person","name":"Linda Armstrong","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong"}],"reviewer":{"@type":"Person","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod#person","name":"Shivani Kharod, Ph.D.","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod"},"dates":{"datePublished":"2025-05-09T13:25:09Z","dateModified":"2025-12-19T10:21:58Z","lastReviewed":"2025-05-09"},"content":{"html":"<nav class=\"breadcrumbs\" aria-label=\"Breadcrumb\"><ol><li><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/\">Home</a></li><li><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/library\">Library</a></li><li><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/medications\">Medications</a></li><li><span aria-current=\"page\">Antiparkinson Agents</span></li></ol></nav><div class=\"article-page article-standard\" data-library-standard><div class=\"article-main-grid\"><header class=\"article-heading\"><h1>Antiparkinson Agents</h1><p class=\"article-inline-credits\"><span>Written by <a class=\"article-credit-person\" href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11501.jpg\" alt=\"\" width=\"22\" height=\"22\" loading=\"lazy\">Linda Armstrong</a></span><span>Medically reviewed by <a class=\"article-credit-person\" href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11505.jpg\" alt=\"\" width=\"22\" height=\"22\" loading=\"lazy\">Shivani Kharod, Ph.D.</a></span></p><div class=\"article-dates\"><span>Published on <time datetime=\"2025-05-09T13:25:09Z\">May 9, 2025</time></span><span aria-hidden=\"true\"> · </span><span>Updated on <time datetime=\"2025-12-19T10:21:58Z\">December 19, 2025</time></span></div></header><div class=\"article-jumpbar\"></div><div class=\"article-layout\"><div class=\"article-reading\"><article class=\"prose\" id=\"article-content\"><div class=\"article-intro\" data-source-field=\"hero\"><p>Antiparkinson agents are specialized medications that address the chemical imbalances in the brain that occur with Parkinson's disease. These substances work by either replacing dopamine, mimicking its effects, or preventing its breakdown in the brain.</p><p>In managing the condition, patients must carefully weigh the benefits and costs of Parkinson's disease medications and their side to develop regimens that effectively address symptoms while maintaining quality of life.</p></div><figure class=\"article-feature\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/library/editorial-17234.webp\" alt=\"A healthcare professional holds a patient&#x27;s hand during a conversation.\" width=\"1200\" height=\"675\" loading=\"eager\" decoding=\"async\"></figure><section class=\"article-takeaways\" aria-labelledby=\"key-takeaways\"><h2 id=\"key-takeaways\">Key takeaways</h2><ul><li>Parkinson’s disease involves progressive dopamine-related changes that affect movement and can also produce nonmotor symptoms.</li><li>Antiparkinson medications replace dopamine, mimic its effects, or slow its breakdown, with treatment tailored to symptoms and side effects.</li><li>Physical, occupational, and speech therapies complement medication to support daily functioning and independence.</li></ul></section><span id=\"parkinson-s-disease-symptoms\" class=\"section-anchor-alias\" data-section-alias=\"parkinsons-disease-symptoms\" aria-hidden=\"true\"></span><h2 id=\"parkinsons-disease-symptoms\">Parkinson’s Disease Symptoms</h2><p>Parkinson's disease is a progressive neurodegenerative disorder that primarily affects movement. It develops when neurons in the brain that produce dopamine, a chemical messenger responsible for coordinated movement, gradually break down or die. </p><p>The disease typically begins around age 60, although early-onset forms can occur before age 50. According to <a href=\"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise?utm_medium=referral&amp;utm_campaign=libra&amp;utm_content=external_resource&amp;utm_id=site-library-antiparkinson-agents&amp;utm_source=mentalhealth.com\" target=\"_blank\" rel=\"nofollow noopener noreferrer\" class=\"article-inline-link\">insights from the National Institute of Neurological Disorders and Stroke</a>, as many as one million Americans are living with Parkinson's disease <a href=\"#parkinsons-disease-challenges-progress-promise\" aria-label=\"Reference 1\" class=\"article-inline-link article-citation\"><sup>[1]</sup></a>. </p><p>The main symptoms of Parkinson's disease include <a href=\"#parkinsons-disease-symptoms-causes\" aria-label=\"Reference 2\" class=\"article-inline-link article-citation\"><sup>[2]</sup></a>:</p><ul class=\"wp-block-list\">\n<li><strong>Bradykinesia:</strong> This means that one has a<strong> </strong>decreased speed of movement.</li>\n<li><strong>Postural Instability:</strong> This can include balance problems and stooped posture.</li>\n<li><strong>Tremor:</strong> This symptom typically begins in one hand.</li>\n<li><strong>Rigidity:</strong> This can include stiffness in the limbs and trunk.</li>\n<li><strong>Speech and Writing Changes:</strong> Examples include slurred or hesitant speech or difficulty writing.</li>\n<li><strong>Loss of Automatic Movements:</strong> These movements include blinking, swinging one’s arms while walking, or smiling.</li>\n<li><strong>Nonmotor Symptoms:</strong> These symptoms can include anxiety, sleep problems, depression, constipation, olfactory issues, impaired memory, or lethargy.</li>\n</ul><h2 id=\"parkinson-s-disease-progression\">Parkinson's Disease Progression</h2><p>Parkinson's disease follows a progressive course that varies significantly from person to person, with symptoms typically developing gradually over years. However, understanding the typical progression patterns helps patients and caregivers anticipate changes and adapt management strategies as needed. </p><ul class=\"wp-block-list\">\n<li><strong>Early-stage Disease: </strong>In early-stage Parkinson's disease, symptoms are typically mild and often confined to one side of the body. Patients may notice a slight tremor in one hand, mild rigidity, or subtle changes in posture and facial expression. These initial symptoms rarely interfere significantly with daily activities and symptoms typically respond well to medication <a href=\"#parkinsons-disease-challenges-progress-promise\" aria-label=\"Reference 1\" class=\"article-inline-link article-citation\"><sup>[1]</sup></a>. </li>\n<li><strong>Mid-stage Disease: </strong>As the disease progresses to mid-stage, symptoms typically affect both sides of the body and become more pronounced. Balance problems emerge, movements slow further, and falls become more common. Medication effects may begin to fluctuate, with some medications decreasing in effectiveness between doses <a href=\"#parkinsons-disease-challenges-progress-promise\" aria-label=\"Reference 1\" class=\"article-inline-link article-citation\"><sup>[1]</sup></a>. </li>\n<li><strong>Advanced Disease: </strong>Advanced Parkinson's disease brings more significant challenges, including the freezing of one’s gait, increased fall risk, and greater difficulty with activities of daily living. Non-motor symptoms often become more prominent, including cognitive changes, hallucinations, sleep disorders, and autonomic dysfunction (i.e. problems with the body’s autonomic nervous system functions, such as heart rate and blood pressure). Many patients develop fluctuating responses to medications, with unpredictable \"on\" and \"off\" periods <a href=\"#treatment-advanced-parkinson-s-disease\" aria-label=\"Reference 3\" class=\"article-inline-link article-citation\"><sup>[3]</sup></a>. </li>\n</ul><p>Disease progression rates vary substantially, with some people experiencing slow progression over decades, while others advance more rapidly. While Parkinson's disease isn't considered fatal, advanced disease can cause complications such as swallowing difficulties, which can in turn lead to aspiration pneumonia (an infection caused by breathing something other than air into the lungs). As a result, these complications can lead to serious health issues.</p><span id=\"parkinson-s-diagnosis-and-treatment-options\" class=\"section-anchor-alias\" data-section-alias=\"parkinsons-diagnosis-and-treatment-options\" aria-hidden=\"true\"></span><h2 id=\"parkinsons-diagnosis-and-treatment-options\">Parkinson’s Diagnosis and Treatment Options</h2><p>Since a specific test to identify Parkinson’s disease doesn’t exist, neurologists diagnose the condition based on a comprehensive medical history, a review of symptoms, and a neurological and physical examination. Tests and procedures used to diagnose the condition include: blood tests and lab tests to rule out other conditions, imaging tests such as MRIs or brain ultrasounds, and dopamine transporter (DAT) scans that can help support the suspicion of Parkinson's disease <a href=\"#parkinsons-disease-diagnosis-treatment\" aria-label=\"Reference 4\" class=\"article-inline-link article-citation\"><sup>[4]</sup></a>. </p><p>Following a diagnosis, treatment usually comprises a multifaceted approach tailored to each person's symptoms and disease stage. Often forming the cornerstone of management, antiparkinson medications are a diverse group of pharmaceutical drugs designed to address the dopamine deficiency that characterizes Parkinson's disease. </p><p>Treatment typically begins when symptoms interfere with daily activities, and medication regimens are carefully tailored to each person's specific symptoms, age, and disease progression. While these medications can significantly restore the balance of neurotransmitters, decrease motor symptoms, and improve quality of life, they primarily manage symptoms rather than altering the underlying disease process <a href=\"#parkinsons-disease-pathogenesis-clinical-aspects\" aria-label=\"Reference 5\" class=\"article-inline-link article-citation\"><sup>[5]</sup></a>. </p><p>Additionally, comprehensive management for Parkinson’s disease also includes rehabilitation therapies that address specific functional limitations, regular exercise, and surgical options <a href=\"#treatment-advanced-parkinson-s-disease\" aria-label=\"Reference 3\" class=\"article-inline-link article-citation\"><sup>[3]</sup></a>. </p><h2 id=\"treatment-with-levodopa-and-carbidopa\">Treatment with Levodopa and Carbidopa</h2><p>Among the arsenal of medications available for Parkinson's disease symptom management, levodopa is one of the most effective <a href=\"#parkinsons-disease-challenges-progress-promise\" aria-label=\"Reference 1\" class=\"article-inline-link article-citation\"><sup>[1]</sup></a>. It crosses the blood-brain barrier and converts to dopamine in the brain to replenish depleted levels. This helps treat Parkinson’s as the disease results in decreased dopamine levels.</p><p>However, when administered alone, only a small fraction of levodopa reaches the brain, as most is metabolized (i.e. converted) to dopamine beforehand in the bloodstream. This typically leads to significant side effects such as nausea, vomiting, and low blood pressure <a href=\"#parkinsons-disease-medications\" aria-label=\"Reference 6\" class=\"article-inline-link article-citation\"><sup>[6]</sup></a>. </p><p>To minimize these side effects, levodopa is usually combined with an enzyme inhibitor drug called carbidopa. This combination allows more levodopa to reach the brain while significantly reducing side effects <a href=\"#parkinsons-disease-medications\" aria-label=\"Reference 6\" class=\"article-inline-link article-citation\"><sup>[6]</sup></a>. Available in several formulations, these medications provide flexibility in managing symptoms at different disease stages <a href=\"#parkinsons-disease-diagnosis-treatment\" aria-label=\"Reference 4\" class=\"article-inline-link article-citation\"><sup>[4]</sup></a>.</p><p>Levodopa/carbidopa therapy typically provides a dramatic improvement in motor symptoms, especially in those with early-stage Parkinson's disease. However, as the disease progresses and more dopamine-producing neurons are lost, the effectiveness of levodopa/carbidopa may diminish, and patients often require higher or more frequent doses <a href=\"#parkinsons-disease-pathogenesis-clinical-aspects\" aria-label=\"Reference 5\" class=\"article-inline-link article-citation\"><sup>[5]</sup></a>. </p><h2 id=\"treatment-with-dopamine-agonists-and-anticholinergics\">Treatment with Dopamine Agonists and Anticholinergics</h2><p>Dopamine agonists are a critical class of antiparkinson medications that work by directly stimulating dopamine receptors in the brain, mimicking the action of natural dopamine. This function is important as Parkinson’s develops when neurons in the brain that produce dopamine break down or die. Unlike the drug levodopa, which requires conversion to dopamine, these medications bind directly to dopamine receptors, activating them even in the absence of dopamine-producing neurons <a href=\"#parkinsons-disease-medications\" aria-label=\"Reference 6\" class=\"article-inline-link article-citation\"><sup>[6]</sup></a>.</p><p>Dopamine agonists are often used in the early stages of Parkinson’s. They can be prescribed alongside levodopa in order to lengthen its duration of effectiveness <a href=\"#parkinsons-disease-medications\" aria-label=\"Reference 6\" class=\"article-inline-link article-citation\"><sup>[6]</sup></a>. Some of the more commonly prescribed dopamine agonists include: pramipexole (Mirapex), apomorphine (Apokyn), and rotigotine (Neupro), the latter of which is offered as a transdermal patch that provides continuous drug delivery over 24 hours <a href=\"#parkinsons-disease-diagnosis-treatment\" aria-label=\"Reference 4\" class=\"article-inline-link article-citation\"><sup>[4]</sup></a>. </p><p>While rarely used today, anticholinergics offer another treatment option for Parkinson's disease symptoms. These medications block the neurotransmitter acetylcholine, helping restore balance between acetylcholine and dopamine. This can lessen Parkinson's symptoms.<br><br>Anticholinergics, including benztropine, orphenadrine, procyclidine, and trihexyphenidyl, are effective for managing tremor. However, they’re less helpful for other symptoms and often include significant side effects. For example, <a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/benztropine-use-dosage-side-effects\" class=\"article-inline-link\">benztropine uses</a> include reducing muscle rigidity and controlling tremor, though side effects such as dry mouth, blurred vision, urinary retention, and confusion limit its use <a href=\"#anticholinergics\" aria-label=\"Reference 7\" class=\"article-inline-link article-citation\"><sup>[7]</sup></a>. </p><h2 id=\"treatment-with-mao-bs-and-amantadine\">Treatment with MAO-Bs and Amantadine</h2><p>Monoamine oxidase B (MAO-B) inhibitors block an enzyme that normally breaks down dopamine in the brain. Thus, MAO-B inhibitors allow naturally produced dopamine and dopamine formed from levodopa to remain active in the brain for longer periods <a href=\"#parkinsons-disease-medications\" aria-label=\"Reference 6\" class=\"article-inline-link article-citation\"><sup>[6]</sup></a>. This further limits symptoms of Parkinson’s, which is characterized by the loss or breakdown of dopamine-producing neurons.<br><br>Commonly used MAO-B inhibitors include <a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/maois\" class=\"article-inline-link\">selegiline (Zelapar, Eldepryl, Emsam)</a>, safinamide (Xadago), and rasagiline (Azilect) <a href=\"#parkinsons-disease-pathogenesis-clinical-aspects\" aria-label=\"Reference 5\" class=\"article-inline-link article-citation\"><sup>[5]</sup></a>. Often used as an initial form of treatment, MAO-Bs can relieve motor symptoms, delay the need for therapy with the drug levodopa, and reduce the risk of levodopa-induced motor complications <a href=\"#parkinsons-disease-pathogenesis-clinical-aspects\" aria-label=\"Reference 5\" class=\"article-inline-link article-citation\"><sup>[5]</sup></a>. </p><p>However, along with side effects such as confusion, nausea, insomnia, and headaches, MAO-Bs can also cause hallucinations, particularly when they’re used alongside the combination of levodopa/carbidopa <a href=\"#parkinsons-disease-diagnosis-treatment\" aria-label=\"Reference 4\" class=\"article-inline-link article-citation\"><sup>[4]</sup></a>. </p><p>In contrast to MAO-Bs, amantadine was originally developed as an antiviral medication for influenza. While researchers don’t fully understand its anti-Parkinson’s effects, <a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/amantadine\" class=\"article-inline-link\">amantadine for Parkinson's disease</a> helps reduce twitching, resting tremors, rigidity, and fatigue. Plus, it can be used to lower the required dosage of levodopa <a href=\"#parkinsons-disease-pathogenesis-clinical-aspects\" aria-label=\"Reference 5\" class=\"article-inline-link article-citation\"><sup>[5]</sup></a>. </p><span id=\"supportive-therapies-for-parkinson-s\" class=\"section-anchor-alias\" data-section-alias=\"supportive-therapies-for-parkinsons\" aria-hidden=\"true\"></span><h2 id=\"supportive-therapies-for-parkinsons\">Supportive Therapies for Parkinson’s</h2><p>Beyond pharmaceutical treatment, comprehensive Parkinson's disease management includes the following range of supportive therapies <a href=\"#treatment-parkinsons-disease\" aria-label=\"Reference 8\" class=\"article-inline-link article-citation\"><sup>[8]</sup></a>: </p><ul class=\"wp-block-list\">\n<li><strong>Physical Therapy:</strong> PT plays a key role in maintaining mobility and flexibility, with therapists designing specialized exercise programs that focus on improving gait, balance, and posture. </li>\n<li><strong>Occupational Therapy:</strong> OT provides strategies and tools to maintain independence in daily activities.</li>\n<li><strong>Speech Therapy: </strong>Speech therapy is a form of <a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/treatment-of-communication-disorders\" class=\"article-inline-link\">treatment for communication disorders</a> that also addresses the swallowing difficulties that often develop with Parkinson’s.</li>\n<li><strong>Nutritional Counseling: </strong>Dietary changes may improve some symptoms or pharmaceutical side effects. For example, added fiber and water consumption can minimize constipation, increased salt and smaller and more frequent meals can aid issues with dizziness and low blood pressure, and elevated caloric consumption can prevent unintentional weight loss.</li>\n</ul><p>For those who don’t respond to medication, advanced Parkinson's disease treatment options offer more invasive steps that may improve motor symptoms. These include deep brain stimulation (DBS) and continuous apomorphine infusions <a href=\"#treatment-advanced-parkinson-s-disease\" aria-label=\"Reference 3\" class=\"article-inline-link article-citation\"><sup>[3]</sup></a>. </p><p>Additionally, treatment options continue to evolve, with several new treatments for Parkinson’s disease showing promise. For example, researchers are working to deliver genes that can increase dopamine production or provide neuroprotection directly to affected brain regions. Cell-based therapies, including the transplantation of stem cells or dopamine-producing cells, aim to replace lost neurons and restore normal function <a href=\"#parkinsons-disease-pathogenesis-clinical-aspects\" aria-label=\"Reference 5\" class=\"article-inline-link article-citation\"><sup>[5]</sup></a>. </p><h2 id=\"living-with-parkinson-s-disease\">Living with Parkinson's Disease</h2><p>Navigating life with Parkinson's disease requires adaptability, resilience, and a proactive approach to health management. While living with Parkinson’s presents unique challenges, comprehensive care and supportive strategies enable many people to maintain fulfilling, active lives for many years after diagnosis. A multidisciplinary approach that combines medication management, rehabilitation therapies, and lifestyle modifications offers the best foundation for maintaining quality of life and independence.</p><p>It’s also important to note that creating a strong support network is invaluable for those living with Parkinson's disease. Family members, friends, healthcare providers, and support groups all play essential roles in providing practical assistance, emotional support, and valuable information. Ongoing advances in treatment options and management strategies provide genuine reasons for optimism in the face of this challenging condition.</p></article><div class=\"article-endmatter\"><section class=\"article-sources\" id=\"references\" data-source-references=\"\" data-reference-list=\"\" data-reference-style=\"author-date-numbered\"><h2 id=\"references-2\">References</h2><ol>\n    <li id=\"parkinsons-disease-challenges-progress-promise\" aria-level=\"1\" data-reference-number=\"1\"><span>National Institute of Neurological disorders and Stroke. (2025, February 25). Parkinson’s disease: Challenges, progress, and promise. National Institute of Neurological disorders and Stroke.<a href=\"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">ninds.nih.gov</a>. Accessed 29 April 2025.</span></li>\n    <li id=\"parkinsons-disease-symptoms-causes\" aria-level=\"1\" data-reference-number=\"2\"><span>Mayo Clinic. (2024, September 27). </span><i><span>Parkinson’s disease: Symptoms and causes. </span></i><span>Mayo Clinic. </span> <a href=\"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Mayo Clinic</a><span>.</span><span> Accessed 29 April 2025.</span></li>\n    <li id=\"treatment-advanced-parkinson-s-disease\" aria-level=\"1\" data-reference-number=\"3\"><span>Giugni, J. C., &amp; Okun, M. S. (2014). Treatment of advanced Parkinson's disease. </span><i><span>Current opinion in neurology,</span></i><span> 27(4), 450–460. </span> <a href=\"https://pmc.ncbi.nlm.nih.gov/articles/PMC4140171/\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">PubMed Central</a><span>. </span><span>Accessed 29 April 2025. </span></li>\n    <li id=\"parkinsons-disease-diagnosis-treatment\" aria-level=\"1\" data-reference-number=\"4\"><span>Mayo Clinic. (2024, September 27). </span><i><span>Parkinson’s disease: Diagnosis and treatment. </span></i><span>Mayo Clinic. </span> <a href=\"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/diagnosis-treatment/drc-20376062\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Mayo Clinic</a><span>. </span><span>Accessed 29 April 2025. </span></li>\n    <li id=\"parkinsons-disease-pathogenesis-clinical-aspects\" aria-level=\"1\" data-reference-number=\"5\"><span>Stoker, T. B., &amp; Greenland, J. C. (Eds.). (2018). </span><i><span>Parkinson’s Disease: Pathogenesis and Clinical Aspects. </span></i><span>Codon Publications. Chapter 7. </span> <a href=\"https://www.ncbi.nlm.nih.gov/books/NBK536726\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">National Library of Medicine</a><span>. </span></li>\n    <li id=\"parkinsons-disease-medications\" aria-level=\"1\" data-reference-number=\"6\"><span>Cleveland  Clinic. (2023, November 9). </span><i><span>Parkinson’s disease medications.</span></i><span> Cleveland Clinic. </span> <a href=\"https://my.clevelandclinic.org/health/treatments/parkinsons-disease-medications\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Cleveland Clinic</a><span>. Accessed 29 April 2025. </span></li>\n    <li id=\"anticholinergics\" aria-level=\"1\" data-reference-number=\"7\"><span>ParkinsonsDisease.net. (2025 April). </span><i><span>What are anticholinergics?</span></i><span>  ParkinsonsDiesease.net. </span> <a href=\"https://parkinsonsdisease.net/medications/anticholinergics\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">What are anticholinergics?</a><span>. Accessed 29 April 2025. </span></li>\n    <li id=\"treatment-parkinsons-disease\" aria-level=\"1\" data-reference-number=\"8\">National Health Service. (2025, November 3). <i>Treatment: Parkinson’s disease.</i> National Health Service. <a href=\"https://www.nhs.uk/conditions/parkinsons-disease/treatment/\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">NHS</a>. Accessed 29 April 2025.</li>\n</ol></section><section class=\"article-medical article-panel\"><h2 id=\"medical-content\">Medical Content</h2><p><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/clinical-affairs\">The Clinical Affairs Team</a> at MentalHealth.com is a dedicated group of medical professionals with diverse and extensive clinical experience. They actively contribute to the development of content, products, and services, and meticulously review all medical material before publication to ensure accuracy and alignment with current research and conversations in mental health. For more information, please visit the <a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/publishing/editorial-policy\">Editorial Policy</a>.</p></section><section class=\"article-about article-panel\"><h2 id=\"about-mentalhealth-com\">About MentalHealth.com</h2><p>MentalHealth.com helps people understand themselves, build healthier relationships, and access the right care. We bring together mental health education, diagnostics, and care management to support well-being throughout every phase of life.</p><div class=\"article-contributors\"><section class=\"article-bio\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11501.jpg\" alt=\"\" width=\"64\" height=\"64\" loading=\"lazy\"><div><p class=\"article-bio-role\">Author</p><h3 id=\"linda-armstrong\"><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong\">Linda Armstrong</a></h3><p class=\"article-bio-credentials\">Writer</p><p>Linda Armstrong is an award-winning writer and editor with over 20 years of experience across print and digital media.</p><dl><div><dt>Published</dt><dd><time datetime=\"2025-05-09T13:25:09Z\">May 9, 2025</time></dd></div><div><dt>Updated</dt><dd><time datetime=\"2025-12-19T10:21:58Z\">December 19, 2025</time></dd></div></dl></div></section><section class=\"article-bio\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11505.jpg\" alt=\"\" width=\"64\" height=\"64\" loading=\"lazy\"><div><p class=\"article-bio-role\">Medical Reviewer</p><h3 id=\"shivani-kharod-ph-d\"><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod\">Shivani Kharod, Ph.D.</a></h3><p class=\"article-bio-credentials\">Ph.D.</p><p>Shivani Kharod, Ph.D. is a medical reviewer with over 10 years of experience in delivering scientifically accurate health content.</p><dl><div><dt>Reviewed</dt><dd><time datetime=\"2025-05-09\">May 9, 2025</time></dd></div></dl></div></section></div></section><section class=\"article-expert article-expert-mobile\" aria-label=\"Subject matter expert\" data-expert-kind=\"related\"><p class=\"article-bio-role\">Subject matter expert</p><div class=\"article-expert-identity\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/3060.webp\" alt=\"\" width=\"64\" height=\"64\" loading=\"lazy\"><h2><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid\">Leila Khurshid, Pharm.D.</a></h2></div><p class=\"article-expert-focus\">Clinical pharmacy and medication</p><a class=\"profile-experience-link experience-button\" href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid\">View experience</a></section><section class=\"article-topic-community article-topic-community-mobile\" aria-label=\"Related communities\"><img class=\"topic-community-banner\" src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/library/editorial-17234.webp\" alt=\"\" width=\"48\" height=\"48\" loading=\"lazy\"><p class=\"topic-community-label\">Related communities</p><h2>Medications</h2><p>Explore questions and perspectives about psychiatric medications and the treatment experience.</p><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/community/medications\">Explore community</a></section></div></div><aside class=\"article-sidebar\" tabindex=\"0\" data-bounded-rail=\"\" aria-label=\"Article navigation and related information\"><details class=\"article-contents\" open data-section-preview=\"3\" data-expanded=\"false\" data-scrolled-past=\"false\"><summary><strong>Table of contents</strong><span aria-hidden=\"true\"></span><small data-current-section=\"\">Choose a section</small></summary><nav aria-label=\"Article contents\"><ol id=\"article-section-list\"><li><a href=\"#parkinsons-disease-symptoms\" title=\"Parkinson’s Disease Symptoms\" aria-label=\"Parkinson’s Disease Symptoms\">Parkinson’s Disease Symptoms</a></li><li><a href=\"#parkinson-s-disease-progression\" title=\"Parkinson's Disease Progression\" aria-label=\"Parkinson's Disease Progression\">Parkinson's Disease Progression</a></li><li><a href=\"#parkinsons-diagnosis-and-treatment-options\" title=\"Parkinson’s Diagnosis and Treatment Options\" aria-label=\"Parkinson’s Diagnosis and Treatment Options\">Parkinson’s Diagnosis and Treatment Options</a></li><li><a href=\"#treatment-with-levodopa-and-carbidopa\" title=\"Treatment with Levodopa and Carbidopa\" aria-label=\"Treatment with Levodopa and Carbidopa\">Treatment with Levodopa and Carbidopa</a></li><li><a href=\"#treatment-with-dopamine-agonists-and-anticholinergics\" title=\"Treatment with Dopamine Agonists and Anticholinergics\" aria-label=\"Treatment with Dopamine Agonists and Anticholinergics\">Treatment with Dopamine Agonists and Anticholinergics</a></li><li><a href=\"#treatment-with-mao-bs-and-amantadine\" title=\"Treatment with MAO-Bs and Amantadine\" aria-label=\"Treatment with MAO-Bs and Amantadine\">Treatment with MAO-Bs and Amantadine</a></li><li><a href=\"#supportive-therapies-for-parkinsons\" title=\"Supportive Therapies for Parkinson’s\" aria-label=\"Supportive Therapies for Parkinson’s\">Supportive Therapies for Parkinson’s</a></li><li><a href=\"#living-with-parkinson-s-disease\" title=\"Living with Parkinson's Disease\" aria-label=\"Living with Parkinson's Disease\">Living with Parkinson's Disease</a></li></ol><button type=\"button\" class=\"article-sections-toggle\" data-sections-toggle aria-controls=\"article-section-list\" aria-expanded=\"false\">View more</button></nav></details><section class=\"article-expert\" aria-label=\"Subject matter expert\" data-expert-kind=\"related\"><p class=\"article-bio-role\">Subject matter expert</p><div class=\"article-expert-identity\"><img src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/3060.webp\" alt=\"\" width=\"64\" height=\"64\" loading=\"lazy\"><h2><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid\">Leila Khurshid, Pharm.D.</a></h2></div><p class=\"article-expert-focus\">Clinical pharmacy and medication</p><a class=\"profile-experience-link experience-button\" href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid\">View experience</a></section><section class=\"article-topic-community\" aria-label=\"Related communities\"><img class=\"topic-community-banner\" src=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/library/editorial-17234.webp\" alt=\"\" width=\"48\" height=\"48\" loading=\"lazy\"><p class=\"topic-community-label\">Related communities</p><h2>Medications</h2><p>Explore questions and perspectives about psychiatric medications and the treatment experience.</p><a href=\"https://mentalhealth-v2.workspace-454808.chatgpt.site/community/medications\">Explore community</a></section></aside></div></div></div>","text":"HomeLibraryMedicationsAntiparkinson AgentsAntiparkinson AgentsWritten by Linda ArmstrongMedically reviewed by Shivani Kharod, Ph.D.Published on May 9, 2025 · Updated on December 19, 2025Antiparkinson agents are specialized medications that address the chemical imbalances in the brain that occur with Parkinson's disease. These substances work by either replacing dopamine, mimicking its effects, or preventing its breakdown in the brain.In managing the condition, patients must carefully weigh the benefits and costs of Parkinson's disease medications and their side to develop regimens that effectively address symptoms while maintaining quality of life.Key takeawaysParkinson’s disease involves progressive dopamine-related changes that affect movement and can also produce nonmotor symptoms.Antiparkinson medications replace dopamine, mimic its effects, or slow its breakdown, with treatment tailored to symptoms and side effects.Physical, occupational, and speech therapies complement medication to support daily functioning and independence.Parkinson’s Disease SymptomsParkinson's disease is a progressive neurodegenerative disorder that primarily affects movement. It develops when neurons in the brain that produce dopamine, a chemical messenger responsible for coordinated movement, gradually break down or die. The disease typically begins around age 60, although early-onset forms can occur before age 50. According to insights from the National Institute of Neurological Disorders and Stroke, as many as one million Americans are living with Parkinson's disease [1]. The main symptoms of Parkinson's disease include [2]: Bradykinesia: This means that one has a decreased speed of movement. Postural Instability: This can include balance problems and stooped posture. Tremor: This symptom typically begins in one hand. Rigidity: This can include stiffness in the limbs and trunk. Speech and Writing Changes: Examples include slurred or hesitant speech or difficulty writing. Loss of Automatic Movements: These movements include blinking, swinging one’s arms while walking, or smiling. Nonmotor Symptoms: These symptoms can include anxiety, sleep problems, depression, constipation, olfactory issues, impaired memory, or lethargy. Parkinson's Disease ProgressionParkinson's disease follows a progressive course that varies significantly from person to person, with symptoms typically developing gradually over years. However, understanding the typical progression patterns helps patients and caregivers anticipate changes and adapt management strategies as needed. Early-stage Disease: In early-stage Parkinson's disease, symptoms are typically mild and often confined to one side of the body. Patients may notice a slight tremor in one hand, mild rigidity, or subtle changes in posture and facial expression. These initial symptoms rarely interfere significantly with daily activities and symptoms typically respond well to medication [1]. Mid-stage Disease: As the disease progresses to mid-stage, symptoms typically affect both sides of the body and become more pronounced. Balance problems emerge, movements slow further, and falls become more common. Medication effects may begin to fluctuate, with some medications decreasing in effectiveness between doses [1]. Advanced Disease: Advanced Parkinson's disease brings more significant challenges, including the freezing of one’s gait, increased fall risk, and greater difficulty with activities of daily living. Non-motor symptoms often become more prominent, including cognitive changes, hallucinations, sleep disorders, and autonomic dysfunction (i.e. problems with the body’s autonomic nervous system functions, such as heart rate and blood pressure). Many patients develop fluctuating responses to medications, with unpredictable \"on\" and \"off\" periods [3]. Disease progression rates vary substantially, with some people experiencing slow progression over decades, while others advance more rapidly. While Parkinson's disease isn't considered fatal, advanced disease can cause complications such as swallowing difficulties, which can in turn lead to aspiration pneumonia (an infection caused by breathing something other than air into the lungs). As a result, these complications can lead to serious health issues.Parkinson’s Diagnosis and Treatment OptionsSince a specific test to identify Parkinson’s disease doesn’t exist, neurologists diagnose the condition based on a comprehensive medical history, a review of symptoms, and a neurological and physical examination. Tests and procedures used to diagnose the condition include: blood tests and lab tests to rule out other conditions, imaging tests such as MRIs or brain ultrasounds, and dopamine transporter (DAT) scans that can help support the suspicion of Parkinson's disease [4]. Following a diagnosis, treatment usually comprises a multifaceted approach tailored to each person's symptoms and disease stage. Often forming the cornerstone of management, antiparkinson medications are a diverse group of pharmaceutical drugs designed to address the dopamine deficiency that characterizes Parkinson's disease. Treatment typically begins when symptoms interfere with daily activities, and medication regimens are carefully tailored to each person's specific symptoms, age, and disease progression. While these medications can significantly restore the balance of neurotransmitters, decrease motor symptoms, and improve quality of life, they primarily manage symptoms rather than altering the underlying disease process [5]. Additionally, comprehensive management for Parkinson’s disease also includes rehabilitation therapies that address specific functional limitations, regular exercise, and surgical options [3]. Treatment with Levodopa and CarbidopaAmong the arsenal of medications available for Parkinson's disease symptom management, levodopa is one of the most effective [1]. It crosses the blood-brain barrier and converts to dopamine in the brain to replenish depleted levels. This helps treat Parkinson’s as the disease results in decreased dopamine levels.However, when administered alone, only a small fraction of levodopa reaches the brain, as most is metabolized (i.e. converted) to dopamine beforehand in the bloodstream. This typically leads to significant side effects such as nausea, vomiting, and low blood pressure [6]. To minimize these side effects, levodopa is usually combined with an enzyme inhibitor drug called carbidopa. This combination allows more levodopa to reach the brain while significantly reducing side effects [6]. Available in several formulations, these medications provide flexibility in managing symptoms at different disease stages [4].Levodopa/carbidopa therapy typically provides a dramatic improvement in motor symptoms, especially in those with early-stage Parkinson's disease. However, as the disease progresses and more dopamine-producing neurons are lost, the effectiveness of levodopa/carbidopa may diminish, and patients often require higher or more frequent doses [5]. Treatment with Dopamine Agonists and AnticholinergicsDopamine agonists are a critical class of antiparkinson medications that work by directly stimulating dopamine receptors in the brain, mimicking the action of natural dopamine. This function is important as Parkinson’s develops when neurons in the brain that produce dopamine break down or die. Unlike the drug levodopa, which requires conversion to dopamine, these medications bind directly to dopamine receptors, activating them even in the absence of dopamine-producing neurons [6].Dopamine agonists are often used in the early stages of Parkinson’s. They can be prescribed alongside levodopa in order to lengthen its duration of effectiveness [6]. Some of the more commonly prescribed dopamine agonists include: pramipexole (Mirapex), apomorphine (Apokyn), and rotigotine (Neupro), the latter of which is offered as a transdermal patch that provides continuous drug delivery over 24 hours [4]. While rarely used today, anticholinergics offer another treatment option for Parkinson's disease symptoms. These medications block the neurotransmitter acetylcholine, helping restore balance between acetylcholine and dopamine. This can lessen Parkinson's symptoms.Anticholinergics, including benztropine, orphenadrine, procyclidine, and trihexyphenidyl, are effective for managing tremor. However, they’re less helpful for other symptoms and often include significant side effects. For example, benztropine uses include reducing muscle rigidity and controlling tremor, though side effects such as dry mouth, blurred vision, urinary retention, and confusion limit its use [7]. Treatment with MAO-Bs and AmantadineMonoamine oxidase B (MAO-B) inhibitors block an enzyme that normally breaks down dopamine in the brain. Thus, MAO-B inhibitors allow naturally produced dopamine and dopamine formed from levodopa to remain active in the brain for longer periods [6]. This further limits symptoms of Parkinson’s, which is characterized by the loss or breakdown of dopamine-producing neurons.Commonly used MAO-B inhibitors include selegiline (Zelapar, Eldepryl, Emsam), safinamide (Xadago), and rasagiline (Azilect) [5]. Often used as an initial form of treatment, MAO-Bs can relieve motor symptoms, delay the need for therapy with the drug levodopa, and reduce the risk of levodopa-induced motor complications [5]. However, along with side effects such as confusion, nausea, insomnia, and headaches, MAO-Bs can also cause hallucinations, particularly when they’re used alongside the combination of levodopa/carbidopa [4]. In contrast to MAO-Bs, amantadine was originally developed as an antiviral medication for influenza. While researchers don’t fully understand its anti-Parkinson’s effects, amantadine for Parkinson's disease helps reduce twitching, resting tremors, rigidity, and fatigue. Plus, it can be used to lower the required dosage of levodopa [5]. Supportive Therapies for Parkinson’sBeyond pharmaceutical treatment, comprehensive Parkinson's disease management includes the following range of supportive therapies [8]: Physical Therapy: PT plays a key role in maintaining mobility and flexibility, with therapists designing specialized exercise programs that focus on improving gait, balance, and posture. Occupational Therapy: OT provides strategies and tools to maintain independence in daily activities. Speech Therapy: Speech therapy is a form of treatment for communication disorders that also addresses the swallowing difficulties that often develop with Parkinson’s. Nutritional Counseling: Dietary changes may improve some symptoms or pharmaceutical side effects. For example, added fiber and water consumption can minimize constipation, increased salt and smaller and more frequent meals can aid issues with dizziness and low blood pressure, and elevated caloric consumption can prevent unintentional weight loss. For those who don’t respond to medication, advanced Parkinson's disease treatment options offer more invasive steps that may improve motor symptoms. These include deep brain stimulation (DBS) and continuous apomorphine infusions [3]. Additionally, treatment options continue to evolve, with several new treatments for Parkinson’s disease showing promise. For example, researchers are working to deliver genes that can increase dopamine production or provide neuroprotection directly to affected brain regions. Cell-based therapies, including the transplantation of stem cells or dopamine-producing cells, aim to replace lost neurons and restore normal function [5]. Living with Parkinson's DiseaseNavigating life with Parkinson's disease requires adaptability, resilience, and a proactive approach to health management. While living with Parkinson’s presents unique challenges, comprehensive care and supportive strategies enable many people to maintain fulfilling, active lives for many years after diagnosis. A multidisciplinary approach that combines medication management, rehabilitation therapies, and lifestyle modifications offers the best foundation for maintaining quality of life and independence.It’s also important to note that creating a strong support network is invaluable for those living with Parkinson's disease. Family members, friends, healthcare providers, and support groups all play essential roles in providing practical assistance, emotional support, and valuable information. Ongoing advances in treatment options and management strategies provide genuine reasons for optimism in the face of this challenging condition.References National Institute of Neurological disorders and Stroke. (2025, February 25). Parkinson’s disease: Challenges, progress, and promise. National Institute of Neurological disorders and Stroke.ninds.nih.gov. Accessed 29 April 2025. Mayo Clinic. (2024, September 27). Parkinson’s disease: Symptoms and causes. Mayo Clinic. Mayo Clinic. Accessed 29 April 2025. Giugni, J. C., & Okun, M. S. (2014). Treatment of advanced Parkinson's disease. Current opinion in neurology, 27(4), 450–460. PubMed Central. Accessed 29 April 2025. Mayo Clinic. (2024, September 27). Parkinson’s disease: Diagnosis and treatment. Mayo Clinic. Mayo Clinic. Accessed 29 April 2025. Stoker, T. B., & Greenland, J. C. (Eds.). (2018). Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications. Chapter 7. National Library of Medicine. Cleveland Clinic. (2023, November 9). Parkinson’s disease medications. Cleveland Clinic. Cleveland Clinic. Accessed 29 April 2025. ParkinsonsDisease.net. (2025 April). What are anticholinergics? ParkinsonsDiesease.net. What are anticholinergics?. Accessed 29 April 2025. National Health Service. (2025, November 3). Treatment: Parkinson’s disease. National Health Service. NHS. Accessed 29 April 2025. Medical ContentThe Clinical Affairs Team at MentalHealth.com is a dedicated group of medical professionals with diverse and extensive clinical experience. They actively contribute to the development of content, products, and services, and meticulously review all medical material before publication to ensure accuracy and alignment with current research and conversations in mental health. For more information, please visit the Editorial Policy.About MentalHealth.comMentalHealth.com helps people understand themselves, build healthier relationships, and access the right care. We bring together mental health education, diagnostics, and care management to support well-being throughout every phase of life.AuthorLinda ArmstrongWriterLinda Armstrong is an award-winning writer and editor with over 20 years of experience across print and digital media.PublishedMay 9, 2025UpdatedDecember 19, 2025Medical ReviewerShivani Kharod, Ph.D.Ph.D.Shivani Kharod, Ph.D. is a medical reviewer with over 10 years of experience in delivering scientifically accurate health content.ReviewedMay 9, 2025Subject matter expertLeila Khurshid, Pharm.D.Clinical pharmacy and medicationView experienceRelated communitiesMedicationsExplore questions and perspectives about psychiatric medications and the treatment experience.Explore communityTable of contentsChoose a sectionParkinson’s Disease SymptomsParkinson's Disease ProgressionParkinson’s Diagnosis and Treatment OptionsTreatment with Levodopa and CarbidopaTreatment with Dopamine Agonists and AnticholinergicsTreatment with MAO-Bs and AmantadineSupportive Therapies for Parkinson’sLiving with Parkinson's DiseaseView moreSubject matter expertLeila Khurshid, Pharm.D.Clinical pharmacy and medicationView experienceRelated communitiesMedicationsExplore questions and perspectives about psychiatric medications and the treatment experience.Explore community","wordCount":2049},"schema":{"@context":"https://schema.org","@graph":[{"@type":"Organization","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/#organization","name":"MentalHealth.com","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/"},{"@type":"WebSite","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/#website","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/","name":"MentalHealth.com","inLanguage":"en-US","publisher":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/#organization"}},{"@type":"BreadcrumbList","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://mentalhealth-v2.workspace-454808.chatgpt.site/"},{"@type":"ListItem","position":2,"name":"Library","item":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library"},{"@type":"ListItem","position":3,"name":"Medications","item":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/medications"},{"@type":"ListItem","position":4,"name":"Antiparkinson Agents","item":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents"}]},{"@type":"ImageObject","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#primaryimage","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/library/editorial-17234.webp","contentUrl":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/library/editorial-17234.webp","width":1200,"height":675,"encodingFormat":"image/webp","caption":"A healthcare professional holds a patient's hand during a conversation."},{"@type":"Person","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong#person","name":"Linda Armstrong","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong","jobTitle":"Writer","image":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11501.jpg","sameAs":["https://www.linkedin.com/in/linda-l-armstrong-5a74342/"]},{"@type":"Person","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod#person","name":"Shivani Kharod, Ph.D.","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod","jobTitle":"Ph.D.","image":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11505.jpg","sameAs":["www.linkedin.com/in/shivanikharod"]},{"@type":"Article","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#article","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents","headline":"Antiparkinson Agents","description":"Explore medication options for Parkinson's disease, including levodopa and supportive therapies to manage symptoms.","wordCount":1683,"mainEntityOfPage":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#webpage"},"publisher":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/#organization"},"articleSection":"Library","citation":[{"@type":"CreativeWork","name":"National Institute of Neurological disorders and Stroke. (2025, February 25). Parkinson’s disease: Challenges, progress, and promise. National Institute of Neurological disorders and Stroke.ninds.nih.gov. Accessed 29 April 2025.","url":"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise"},{"@type":"CreativeWork","name":"Mayo Clinic. (2024, September 27). Parkinson’s disease: Symptoms and causes. Mayo Clinic. Mayo Clinic. Accessed 29 April 2025.","url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055"},{"@type":"CreativeWork","name":"Giugni, J. C., & Okun, M. S. (2014). Treatment of advanced Parkinson's disease. Current opinion in neurology, 27(4), 450–460. PubMed Central. Accessed 29 April 2025.","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4140171/"},{"@type":"CreativeWork","name":"Mayo Clinic. (2024, September 27). Parkinson’s disease: Diagnosis and treatment. Mayo Clinic. Mayo Clinic. Accessed 29 April 2025.","url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/diagnosis-treatment/drc-20376062"},{"@type":"CreativeWork","name":"Stoker, T. B., & Greenland, J. C. (Eds.). (2018). Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications. Chapter 7. National Library of Medicine.","url":"https://www.ncbi.nlm.nih.gov/books/NBK536726"},{"@type":"CreativeWork","name":"Cleveland Clinic. (2023, November 9). Parkinson’s disease medications. Cleveland Clinic. Cleveland Clinic. Accessed 29 April 2025.","url":"https://my.clevelandclinic.org/health/treatments/parkinsons-disease-medications"},{"@type":"CreativeWork","name":"ParkinsonsDisease.net. (2025 April). What are anticholinergics? ParkinsonsDiesease.net. What are anticholinergics?. Accessed 29 April 2025.","url":"https://parkinsonsdisease.net/medications/anticholinergics"},{"@type":"CreativeWork","name":"National Health Service. (2025, November 3). Treatment: Parkinson’s disease. National Health Service. NHS. Accessed 29 April 2025.","url":"https://www.nhs.uk/conditions/parkinsons-disease/treatment/"}],"inLanguage":"en-US","datePublished":"2025-05-09T13:25:09Z","dateModified":"2025-12-19T10:21:58Z","author":[{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong#person"}],"image":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#primaryimage"}},{"@type":"MedicalWebPage","@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#webpage","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents","name":"Antiparkinson Agents","description":"Explore medication options for Parkinson's disease, including levodopa and supportive therapies to manage symptoms.","inLanguage":"en-US","isPartOf":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/#website"},"breadcrumb":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#breadcrumb"},"mainEntity":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#article"},"relatedLink":["https://mentalhealth-v2.workspace-454808.chatgpt.site/library/amphetamines","https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antipsychotics","https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antidepressants","https://mentalhealth-v2.workspace-454808.chatgpt.site/library/opioids","https://mentalhealth-v2.workspace-454808.chatgpt.site/library/are-antipsychotics-addictive","https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid"],"publisher":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/#organization"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"General public"},"datePublished":"2025-05-09T13:25:09Z","dateModified":"2025-12-19T10:21:58Z","lastReviewed":"2025-05-09","primaryImageOfPage":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#primaryimage"},"image":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#primaryimage"},"reviewedBy":{"@id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod#person"}}]},"representations":{"html":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents","json":"https://mentalhealth-v2.workspace-454808.chatgpt.site/data/library/antiparkinson-agents.json","jsonLd":"https://mentalhealth-v2.workspace-454808.chatgpt.site/data/library/antiparkinson-agents.ld.json"},"$schema":"https://mentalhealth-v2.workspace-454808.chatgpt.site/data/page.schema.json","images":[{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11501.jpg","alt":"","width":22,"height":22},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/11505.jpg","alt":"","width":22,"height":22},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/library/editorial-17234.webp","alt":"A healthcare professional holds a patient's hand during a conversation.","width":1200,"height":675},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/wordpress/3060.webp","alt":"","width":64,"height":64}],"sections":[{"id":"key-takeaways","title":"Key takeaways","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#key-takeaways"},{"id":"parkinsons-disease-symptoms","title":"Parkinson’s Disease Symptoms","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-symptoms"},{"id":"parkinson-s-disease-progression","title":"Parkinson's Disease Progression","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinson-s-disease-progression"},{"id":"parkinsons-diagnosis-and-treatment-options","title":"Parkinson’s Diagnosis and Treatment Options","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-diagnosis-and-treatment-options"},{"id":"treatment-with-levodopa-and-carbidopa","title":"Treatment with Levodopa and Carbidopa","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-with-levodopa-and-carbidopa"},{"id":"treatment-with-dopamine-agonists-and-anticholinergics","title":"Treatment with Dopamine Agonists and Anticholinergics","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-with-dopamine-agonists-and-anticholinergics"},{"id":"treatment-with-mao-bs-and-amantadine","title":"Treatment with MAO-Bs and Amantadine","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-with-mao-bs-and-amantadine"},{"id":"supportive-therapies-for-parkinsons","title":"Supportive Therapies for Parkinson’s","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#supportive-therapies-for-parkinsons"},{"id":"living-with-parkinson-s-disease","title":"Living with Parkinson's Disease","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#living-with-parkinson-s-disease"},{"id":"references-2","title":"References","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#references-2"},{"id":"medical-content","title":"Medical Content","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#medical-content"},{"id":"about-mentalhealth-com","title":"About MentalHealth.com","level":2,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#about-mentalhealth-com"},{"id":"linda-armstrong","title":"Linda Armstrong","level":3,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#linda-armstrong"},{"id":"shivani-kharod-ph-d","title":"Shivani Kharod, Ph.D.","level":3,"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#shivani-kharod-ph-d"}],"references":[{"number":1,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-challenges-progress-promise","text":"National Institute of Neurological disorders and Stroke. (2025, February 25). Parkinson’s disease: Challenges, progress, and promise. National Institute of Neurological disorders and Stroke.ninds.nih.gov. Accessed 29 April 2025.","links":[{"url":"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise","label":"ninds.nih.gov"}],"url":"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise"},{"number":2,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-symptoms-causes","text":"Mayo Clinic. (2024, September 27). Parkinson’s disease: Symptoms and causes. Mayo Clinic. Mayo Clinic. Accessed 29 April 2025.","links":[{"url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055","label":"Mayo Clinic"}],"url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055"},{"number":3,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-advanced-parkinson-s-disease","text":"Giugni, J. C., & Okun, M. S. (2014). Treatment of advanced Parkinson's disease. Current opinion in neurology, 27(4), 450–460. PubMed Central. Accessed 29 April 2025.","links":[{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4140171/","label":"PubMed Central"}],"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4140171/"},{"number":4,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-diagnosis-treatment","text":"Mayo Clinic. (2024, September 27). Parkinson’s disease: Diagnosis and treatment. Mayo Clinic. Mayo Clinic. Accessed 29 April 2025.","links":[{"url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/diagnosis-treatment/drc-20376062","label":"Mayo Clinic"}],"url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/diagnosis-treatment/drc-20376062"},{"number":5,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","text":"Stoker, T. B., & Greenland, J. C. (Eds.). (2018). Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications. Chapter 7. National Library of Medicine.","links":[{"url":"https://www.ncbi.nlm.nih.gov/books/NBK536726","label":"National Library of Medicine"}],"url":"https://www.ncbi.nlm.nih.gov/books/NBK536726"},{"number":6,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-medications","text":"Cleveland Clinic. (2023, November 9). Parkinson’s disease medications. Cleveland Clinic. Cleveland Clinic. Accessed 29 April 2025.","links":[{"url":"https://my.clevelandclinic.org/health/treatments/parkinsons-disease-medications","label":"Cleveland Clinic"}],"url":"https://my.clevelandclinic.org/health/treatments/parkinsons-disease-medications"},{"number":7,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#anticholinergics","text":"ParkinsonsDisease.net. (2025 April). What are anticholinergics? ParkinsonsDiesease.net. What are anticholinergics?. Accessed 29 April 2025.","links":[{"url":"https://parkinsonsdisease.net/medications/anticholinergics","label":"What are anticholinergics?"}],"url":"https://parkinsonsdisease.net/medications/anticholinergics"},{"number":8,"id":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-parkinsons-disease","text":"National Health Service. (2025, November 3). Treatment: Parkinson’s disease. National Health Service. NHS. Accessed 29 April 2025.","links":[{"url":"https://www.nhs.uk/conditions/parkinsons-disease/treatment/","label":"NHS"}],"url":"https://www.nhs.uk/conditions/parkinsons-disease/treatment/"}],"relatedReading":[],"links":[{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/","label":"Home"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library","label":"Library"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/medications","label":"Medications"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong","label":"Linda Armstrong"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod","label":"Shivani Kharod, Ph.D."},{"url":"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise?utm_medium=referral&utm_campaign=libra&utm_content=external_resource&utm_id=site-library-antiparkinson-agents&utm_source=mentalhealth.com","label":"insights from the National Institute of Neurological Disorders and Stroke"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-challenges-progress-promise","label":"[1]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-symptoms-causes","label":"[2]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-challenges-progress-promise","label":"[1]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-challenges-progress-promise","label":"[1]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-advanced-parkinson-s-disease","label":"[3]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-diagnosis-treatment","label":"[4]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","label":"[5]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-advanced-parkinson-s-disease","label":"[3]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-challenges-progress-promise","label":"[1]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-medications","label":"[6]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-medications","label":"[6]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-diagnosis-treatment","label":"[4]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","label":"[5]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-medications","label":"[6]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-medications","label":"[6]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-diagnosis-treatment","label":"[4]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/benztropine-use-dosage-side-effects","label":"benztropine uses"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#anticholinergics","label":"[7]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-medications","label":"[6]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/maois","label":"selegiline (Zelapar, Eldepryl, Emsam)"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","label":"[5]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","label":"[5]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-diagnosis-treatment","label":"[4]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/amantadine","label":"amantadine for Parkinson's disease"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","label":"[5]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-parkinsons-disease","label":"[8]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/treatment-of-communication-disorders","label":"treatment for communication disorders"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-advanced-parkinson-s-disease","label":"[3]"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-pathogenesis-clinical-aspects","label":"[5]"},{"url":"https://www.ninds.nih.gov/current-research/focus-disorders/parkinsons-disease-research/parkinsons-disease-challenges-progress-and-promise","label":"ninds.nih.gov"},{"url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055","label":"Mayo Clinic"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4140171/","label":"PubMed Central"},{"url":"https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/diagnosis-treatment/drc-20376062","label":"Mayo Clinic"},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK536726","label":"National Library of Medicine"},{"url":"https://my.clevelandclinic.org/health/treatments/parkinsons-disease-medications","label":"Cleveland Clinic"},{"url":"https://parkinsonsdisease.net/medications/anticholinergics","label":"What are anticholinergics?"},{"url":"https://www.nhs.uk/conditions/parkinsons-disease/treatment/","label":"NHS"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/clinical-affairs","label":"The Clinical Affairs Team"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/publishing/editorial-policy","label":"Editorial Policy"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/linda-armstrong","label":"Linda Armstrong"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/shivani-kharod","label":"Shivani Kharod, Ph.D."},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid","label":"Leila Khurshid, Pharm.D."},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid","label":"View experience"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/community/medications","label":"Explore community"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-disease-symptoms","label":"Parkinson’s Disease Symptoms"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinson-s-disease-progression","label":"Parkinson's Disease Progression"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#parkinsons-diagnosis-and-treatment-options","label":"Parkinson’s Diagnosis and Treatment Options"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-with-levodopa-and-carbidopa","label":"Treatment with Levodopa and Carbidopa"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-with-dopamine-agonists-and-anticholinergics","label":"Treatment with Dopamine Agonists and Anticholinergics"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#treatment-with-mao-bs-and-amantadine","label":"Treatment with MAO-Bs and Amantadine"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#supportive-therapies-for-parkinsons","label":"Supportive Therapies for Parkinson’s"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents#living-with-parkinson-s-disease","label":"Living with Parkinson's Disease"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid","label":"Leila Khurshid, Pharm.D."},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/people/leila-khurshid","label":"View experience"},{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/community/medications","label":"Explore community"}],"seo":{"title":"Antiparkinson Agents | MentalHealth.com","description":"Explore medication options for Parkinson's disease, including levodopa and supportive therapies to manage symptoms.","canonical":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents","robots":"index,follow","socialImage":{"url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/assets/social-tiles-20261006-dots/library.png","width":1200,"height":630,"alt":"MentalHealth.com — Library","type":"image/png","sitemapGroup":"library"}},"breadcrumbs":[{"name":"Home","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/"},{"name":"Library","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library"},{"name":"Medications","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/medications"},{"name":"Antiparkinson Agents","url":"https://mentalhealth-v2.workspace-454808.chatgpt.site/library/antiparkinson-agents"}],"subjectMatterExpert":{"name":"Leila Khurshid, Pharm.D.","url":"/people/leila-khurshid","profileId":"2317","topic":"medication","focus":"Clinical pharmacy and medication","selectionBasis":"Documented expertise in the existing published profile","reviewAttribution":false},"keyTakeaways":["Parkinson’s disease involves progressive dopamine-related changes that affect movement and can also produce nonmotor symptoms.","Antiparkinson medications replace dopamine, mimic its effects, or slow its breakdown, with treatment tailored to symptoms and side effects.","Physical, occupational, and speech therapies complement medication to support daily functioning and independence."],"introduction":{"html":"Antiparkinson agents are specialized medications that address the chemical imbalances in the brain that occur with Parkinson's disease. These substances work by either replacing dopamine, mimicking its effects, or preventing its breakdown in the brain.\n\nIn managing the condition, patients must carefully weigh the benefits and costs of Parkinson's disease medications and their side to develop regimens that effectively address symptoms while maintaining quality of life.","text":"Antiparkinson agents are specialized medications that address the chemical imbalances in the brain that occur with Parkinson's disease. These substances work by either replacing dopamine, mimicking its effects, or preventing its breakdown in the brain. In managing the condition, patients must carefully weigh the benefits and costs of Parkinson's disease medications and their side to develop regimens that effectively address symptoms while maintaining quality of life.","sourceField":"hero"},"navigation":[{"label":"Parkinson’s Disease Symptoms","href":"#parkinsons-disease-symptoms","heading":"Parkinson’s Disease Symptoms"},{"label":"Parkinson's Disease Progression","href":"#parkinson-s-disease-progression","heading":"Parkinson's Disease Progression"},{"label":"Parkinson’s Diagnosis and Treatment Options","href":"#parkinsons-diagnosis-and-treatment-options","heading":"Parkinson’s Diagnosis and Treatment Options"},{"label":"Treatment with Levodopa and Carbidopa","href":"#treatment-with-levodopa-and-carbidopa","heading":"Treatment with Levodopa and Carbidopa"},{"label":"Treatment with Dopamine Agonists and Anticholinergics","href":"#treatment-with-dopamine-agonists-and-anticholinergics","heading":"Treatment with Dopamine Agonists and Anticholinergics"},{"label":"Treatment with MAO-Bs and Amantadine","href":"#treatment-with-mao-bs-and-amantadine","heading":"Treatment with MAO-Bs and Amantadine"},{"label":"Supportive Therapies for Parkinson’s","href":"#supportive-therapies-for-parkinsons","heading":"Supportive Therapies for Parkinson’s"},{"label":"Living with Parkinson's Disease","href":"#living-with-parkinson-s-disease","heading":"Living with Parkinson's Disease"}],"relatedCommunity":{"community":"/community/medications","basis":"topic match"},"referencePresentation":"Numbered author–date bibliography with linked source documents; n.d. denotes unavailable publication date.","collections":[]}
